From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
This article was originally published in The Pink Sheet Daily
Executive Summary
Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.